Goldman Sachs Turns Bearish on MoonLake Goldman Sachs downgraded MoonLake Immunotherapeutics to Sell, citing high approval risks despite progress in Phase 3 trials. Credit: MoonLake Subscribe now Already have an account? Sign in.
